MétaCan
Menu
Back to cohort
Record W4312086633 · doi:10.1002/alz.068223

A Quantitative‐EEG Assessment of Alpha‐1062, a Novel Pro‐Drug of Galantamine for the Treatment of Mild to Moderate Dementia Associated with Alzheimer’s Disease.

2022· article· en· W4312086633 on OpenAlexaff
Denis G. Kay, Ellen Stijl‐’t Hart, C. J. G. Bakker, Klaus Linkenkaer‐Hansen, Frederick D. Sancilio, J. Bryce Ortiz, Geert Jan Groeneveld, Simon‐Shlomo Poil

Bibliographic record

VenueAlzheimer s & Dementia · 2022
Typearticle
Languageen
FieldChemistry
TopicChemical synthesis and alkaloids
Canadian institutionsAlpha Technologies (Canada)
Fundersnot available
KeywordsGalantamineAcetylcholinesteraseNicotinic agonistAlpha (finance)PharmacologyCholinergicPsychologyElectroencephalographyDonepezilDementiaMedicineInternal medicineNeuroscienceChemistryDiseaseReceptorDevelopmental psychologyPsychometrics

Abstract

fetched live from OpenAlex

Abstract Background Acetylcholinesterase inhibitors (AChEIs) enhance cognitive functioning in Alzheimer’s disease (AD). The use of AChEIs at therapeutic doses is limited by gastrointestinal (GI) side effects, such as nausea, vomiting and diarrhea. Alpha‐1062 is a pharmacologically inactive prodrug of the AChEI galantamine specifically designed to reduce or eliminate GI side effects and provide increased safety. In addition to its activity as an AChEI, galantamine exhibits a second important mechanism of action, binding allosterically to nicotinic cholinergic receptors enhancing their responsiveness to acetylcholine. In Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in young and elderly healthy subjects, Alpha‐1062 demonstrated both evidence of an improved GI side effect profile and enhanced cognition. Here we extend the findings of the SAD and MAD studies with an additional analysis of the effects of Alpha‐1062 on quantitative‐EEG (qEEG) data collected as part of the MAD study. Methods Subjects (n = 12/dose) were administered two doses per day of Alpha‐1062 for 7 consecutive days. Pharmaco‐EEG measurements were performed for 4 min eyes closed / 4 min eyes open, on day 1 and day 7 at various timepoints both pre‐dose and post‐dose using a standard 10‐20 electrode montage with 21 channels. qEEG data analysis was conducted using qEEG indices developed using a machine learning algorithm based on the analysis of 39 AD patients administered galantamine ( Sci Rep 7 , 5775 [2017]). These were an AD index and a galantamine index, which were expected to be sensitive to the effects of Alpha 1062 administration. Results In healthy elderly subjects, Alpha‐1062 administration improved response on the AD index (p <0.05) compared to placebo, at the pre‐dose timepoint on day 7. The AD index was also reduced at all post‐dose timepoints on day 7 relative to placebo. Changes in several other relevant measures of qEEG function suggested Alpha‐1062 improved brain function. Conclusion These data demonstrate the potential benefit Alpha‐1062 in the treatment of AD. Alpha‐1062 was safe in the dose range investigated, and influenced pharmaco‐EEG outcomes in healthy elderly subjects that were consistent with the previously documented positive effects in tests related to sustained attention and working memory.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.119
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.306
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicChemical synthesis and alkaloidsFrench-language works237,207